Organon & Co. Hits 52-Week Low at $6.02 Amidst Significant Decline

Organon & Co., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 6.02 as of March 20, 2026. This significant decline marks a staggering 70.88% drop in the stock's performance over the past year, contrasting sharply with the S&P 500's gain of 14.9% during the same period. The company's market capitalization stands at USD 1,650 million, with a price-to-earnings (P/E) ratio of 3.00, indicating a low valuation relative to earnings. Despite a dividend yield of 0.94%, Organon has faced challenges reflected in its financial metrics. The return on equity (ROE) is at 0.00%, and the inventory turnover ratio has hit a low of 2 times, suggesting inefficiencies in managing inventory. Additionally, the company has reported a decline in net profit, which fell by 35.56% to USD 142.47 million. The rise in raw material costs by 6.27% year-over-year further complicates its financial landscape. Overall, Organon & Co. continues to navigate a difficult market environment, as evidenced by its recent stock performance and financial indicators.